Showing results (231-240 of 513) with videos related to

Sort By:
Pageof 52
BMC Cancer|August 25, 2010
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategySu-Jung Kim, Jin Won Kim, Sae-Won Han, et al.
Academic Radiology|August 14, 2012
Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomasWoong Jae Lee, Seung Hong Choi, Chul-Kee Park, et al.
Translational Oncology|October 16, 2012
The Changes in MGMT Promoter Methylation Status in Initial and Recurrent GlioblastomasChul-Kee Park, Ja Eun Kim, Ji Young Kim, et al.
Journal of Korean Medical Science|July 22, 2014
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in KoreaSo Hyun Bae, Min-Jung Park, Min Mi Lee, et al.
Thyroid : Official Journal of the American Thyroid Association|November 7, 2015
Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid CarcinomaDoh Young Lee, Jae-Kyung Won, Se-Hoon Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapyKyung-Hun Lee, Se-Hoon Lee, Dong-Wan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|August 14, 2009
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancerJong-Mu Sun, Do-Youn Oh, Se-Hoon Lee, et al.
BMC Cancer|March 2, 2016
Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasisSoojin Cha, Jeongeun Lee, Jong-Yeon Shin, et al.
The EPMA Journal|December 27, 2021
Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategiesJae Gwang Park, Beom Kyu Choi, Youngjoo Lee, et al.
Cancer Medicine|April 19, 2022
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitorsMinsuk Kwon, Bo Mi Ku, Steve Olsen, et al.
Pageof 52